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Thrombospondin-1 is a matricellular protein with potent antitumour activities, the levels of which
determine the fate of many different tumours, including renal carcinomas. However, the factors that
regulate this protein remain unclear. In renal carcinomas, hypoxic conditions enhance the expression of
angiogenic factors that help adapt tumour cells to their hostile environment. Therefore, we hypothesized
that anti-angiogenic factors should correspondingly be dampened. Indeed, we found that hypoxia decreased
the thrombospondin-1 protein in several clear cell renal carcinoma cell lines (ccRCC), although no
transcriptional regulation was observed. Furthermore, we proved that hypoxia stimulates multiple signals
that independently contribute to diminish thrombospondin-1 in ccRCC, which include a decrease in the
activity of oxygen-dependent prolylhydroxylases (PHDs) and activation of the PI3K/Akt signalling pathway.
In addition, thrombospondin-1 regulation in hypoxia proved to be important for ccRCC cell migration and
invasion.
C
lear cell renal cell carcinomas (ccRCC) are highly vascularized tumours, in part due to the increase in the
levels of angiogenic factors associated with these tumours, such as the vascular endothelial growth factor
(VEGF)1. The angiogenic factors associated with these carcinomas are mostly regulated by the hypoxia-
inducible transcription factors, HIFs (reviewed in2). These factors are stabilized in ccRCC in which the von
Hippel-Lindau (vhl) tumour suppressor gene is lost or mutated, or when oxygen availability is decreased.
Diminished oxygen availability is a common feature of malignant tumours and in fact, it is regarded as trigger
for enhanced proliferation and metastasis. The hypoxia generated during tumour growth involves a cell adaptive
response aimed at restoring the oxygen supply and maintaining cell viability2. Most responses to hypoxia are
mediated through the specific gene expression programs regulated by HIFs, heterodimeric transcription factors
composed of a constitutively expressed beta subunit (HIFb) and an oxygen-regulated alpha subunit (HIFa). In
normoxic conditions HIFa subunits are extremely unstable and their integrity is dependent on hydroxylation by
oxygen-dependent prolyl hydroxylases (PHD1, PHD2 and PHD3)3,4. These enzymes requiremolecular oxygen as
co-substrate for their catalytic activity, and they are therefore believed to act as oxygen sensors that directly
control HIF stability/activity in response to variations in oxygenation. Under normoxic conditions, HIFa pro-
teins are hydroxylated on specific residues and then polyubiquitinated by the VHL-E3 ubiquitin ligase complex,
provoking their degradation by the proteasome5,6. However, while HIFs control most hypoxic responses, other
HIF-independent responses to hypoxia have been described7,8.
Hypoxia alters the balance between pro- and anti-angiogenic factors, favoring the stimulation of angiogenesis9.
Therefore, enhanced angiogenesis in response to hypoxia is part of an adaptive response aimed at achieving
increased oxygen and nutrient delivery to growing tissues. Although the regulation of genes that inhibit angio-
genesis is also important in order to maintain tumour homeostasis, little attention has been paid to the effects of
hypoxia in the regulation of anti-angiogenic factors. One of the best known inhibitors of angiogenesis is the
matricellular protein thrombospondin-1 (TSP-1)10,11. TSP-1 is a multifunctional protein that belongs to a family
of five extracellular matrix proteins with similar structures12. TSP-1 was the first endogenous angiogenesis
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inhibitor identified, and its expression is considered critical for the
maintenance of an anti-angiogenic microenvironment. Indeed, TSP-
1 loss is associated with tumour metastasis and poor outcome
(Reviewed by13), although in other tumour types TSP-1 can promote
tumour growth and metastasis14–16. TSP-1 modulates biological pro-
cesses such as cell adhesion, motility, proliferation, cell-cell and cell-
matrix interactions12,17,18. In addition to its anti-angiogenic effects,
other activities fulfilled by TSP-1 are also important in tumour
development, including the positive modulation of innate anti-
tumour immunity19 and the regulation of tumour blood flow20.
TSP-1 expression is frequently lost during malignant transformation
due to the inactivation of tumour suppressor genes such as p53 and
PTEN21,22, while TSP-1 expressionmay be repressed by the activation
of oncogenes like Myc, Id1, src, c-Jun, ras and HER223–28. Addi-
tionally, DNA hypermethylation can also diminish TSP-1 levels29.
Positive and negative regulation of TSP-1 by hypoxia has been
described in several publications, indicating that hypoxia effects on
TSP-1 levels are clearly cell type dependent30–37. Here, we have exam-
ined the effects of hypoxia on TSP-1 regulation in ccRCC cell lines,
demonstrating that hypoxia stimulates multiple signals that contrib-
ute independently to decrease TSP1 levels, affecting ccRCC migra-
tion and invasion.
Results
Oxygen availability regulates TSP-1 protein levels in ccRCC cells.
Previous studies have indicated that TSP-1 levels are associated with
advanced tumour stage in patients with ccRCC, its expression having
a significant impact on survival38. On the other hand TSP-1 levels are
generally lower in renal carcinoma cells than in normal renal cells39.
Since tumour hypoxia alters the balance between pro- and anti-
angiogenic factors, favouring the expression of the former, we
hypothesized that it might also reduce the expression of angiogenic
inhibitors. Thus, we examined the effect of hypoxia on the expression
of TSP-1 in several ccRCC cell lines. TSP-1 is a matricellular protein,
mostly secreted to the extracellular space, thus we analyzed the
soluble TSP-1 secreted into the conditioned media, as well as total
lysates of monolayer cultures containing the membrane and matrix
bound together with the intracellular protein. We found that TSP-1
protein levels from concentrated conditioned media (100x) were
very low, and they were not significantly affected when cells were
cultured under hypoxic conditions (Fig. 1a). The same results were
observed when secreted soluble protein was analyzed by ELISA (see
Supplementary Fig. S1 online). However, we found that TSP-1
protein levels were significantly lower in response to hypoxia in
the total lysates of all the cell lines analyzed (Fig. 1a). To analyze
the amount of intracellular TSP-1 in our total lysate, the cells were
recovered with EDTA or trypsin before preparing the lysate, such
that extracellular bound TSP-1 did not contribute to the lysate.
Surprisingly, negligible amounts of TSP-1 were observed in these
intracellular cell lysates (see Supplementary Fig. S2 online),
indicating that most of the TSP-1 analyzed in our total lysates
corresponded to membrane and matrix bound TSP-1 protein.
Since hypoxia did not significantly change the levels of TSP-1
mRNA (Fig. 1b left), the loss of this protein under these conditions
did not appear to occur at the transcriptional level. By contrast, the
mRNA levels of VEGF, a known hypoxia-regulated gene, were up-
regulated as expected (Fig. 1b right). In addition, TSP-1 protein was
regulated by oxygen availability in a concentration-dependent man-
ner, since lowering the oxygen concentration from 1% O2 (hypoxia)
to 0.1% O2 (considered as anoxia) produced a greater decrease in
protein levels (Fig. 1c left). To confirm the specific effects of hypoxia
on the TSP-1 protein and given that most of hypoxic responses are
reverted after reoxygenation, the cells were reoxygenated for 12, 24
and 48 h after an initial 24 h period of hypoxia. There was an
increase of TSP-1 protein levels 12 h after reoxygenation, which rose
close to the normoxic levels (Fig. 1c right), indicating that the hyp-
oxic effects on TSP-1 protein levels are specific and reversible.
Hypoxia decreases TSP-1 protein levels independently ofHIF.The
HIF family of transcription factors are considered to be the master
regulators of hypoxia-regulated genes. Because the above results
indicated no transcriptional regulation of TSP-1 in hypoxia, HIF
was not expected to directly influence this protein. However, we
assessed the possibility that HIF might indirectly down-regulate
TSP-1 protein levels during hypoxia by analyzing the effects of
specific siRNAs to knock down the two most known HIF isoforms,
HIF-2a andHIF-1a in the 786-O and RCC4 cell lines. Silencing these
factors did not prevent the decrease in TSP-1 protein associated with
hypoxia (Fig. 2). Therefore, from these results we concluded that the
loss of TSP-1 in ccRCCmediated by hypoxia occurs independently of
HIF.
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Figure 1 | Effect of hypoxia on TSP-1 levels in ccRCC cell lines. a) 786-O
and RCC4 cells were cultured under normoxic (Nx) or hypoxic (Hp)
conditions for 24 h and TSP-1 protein levels in total lysates (TL) or
conditioned media (CM) were analyzed in Western blots b) TSP-1 and
VEGFmRNA levels were determined by quantitative real time PCR in 786-
O and RCC4 cell lines cultured for 24 h under normoxic or hypoxic
conditions. Gene expression was represented as the fold induction against
the levels in normoxic conditions after mRNA levels were normalized to b-
actin. The values represent the average from at least three different
experiments. c) Analysis of TSP-1 protein in RCC4 cells exposed to
normoxia, hypoxia or anoxia (Ax, 0.1% O2) for 24 h (left) and then
reoxygenated for the times indicated (right). A representative experiment
of n54 performed is shown. As a loading control a-tubulin was used in all
panels.
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Akt signalling contributes to the hypoxia-induced down-regu-
lation of TSP-1 protein. Activation of the PI3K/Akt signalling
pathway is responsible for the diminished TSP-1 levels in tumour-
associated endothelial cells from RCC40. On the other hand, acti-
vation of Akt by hypoxia has been reported by other authors41,42.
Hence, we investigated whether Akt signalling regulated TSP-1 in
our ccRCC cell lines exposed to hypoxia. Initially, we evaluated the
effect of the PI3K inhibitor LY294002 on TSP-1 protein levels in
RCC4 cells cultured under normoxic or hypoxic conditions. Hypoxia
increased Akt phosphorylation in these cell lines, an effect that was
inhibited in the presence of LY294002. In parallel to this Akt
activation, TSP-1 protein levels decreased, although they recovered
significantly when hypoxia was induced in the presence of LY294002
(Fig. 3a). To further assess the role of this signalling pathway in the
regulation of TSP-1 by hypoxia, RCC4 cells were transfected with a
plasmid encoding a constitutively active form of Akt (gagAkt). Akt
phosphorylation was enhanced in cells transfected with the cons-
titutively active Akt, yet more importantly, this active Akt induced a
robust decrease in TSP-1 protein when compared to cells transfected
with the empty vector (pCMV6) (Fig. 3c). These effects were only
evident at the protein level, and TSP-1 mRNA was not affected by
the presence of LY294002 (Fig. 3b) or when cells were transfected
with gagAkt (Fig. 3d).
The decrease of TSP-1 provoked by hypoxia is modulated by
PHDs. Other components of the oxygen signalling pathway are
the prolylhydroxylases (PHDs), considered to be the main oxygen
sensors that respond to hypoxia. Since the activity of these enzymes
significantly dampened in hypoxia43, RCC4 cells in normoxia were
treated with dimethyloxaloylglycine (DMOG), a widely used inhi-
bitor of these enzymes. As during hypoxia, TSP-1 mRNA levels did
not change significantly in the presence of DMOG, while Glut-1
mRNA, a well-known target of HIF, showed the expected up-
regulation (Fig. 4a left). Interestingly, exposure to DMOG dimi-
nished the amount of TSP-1 protein in a concentration-dependent
fashion (Fig. 4a right). Furthermore, we could not detect TSP-1 in the
conditioned media from cells treated with DMOG (see Supple-
mentary Fig. S3 online). To further demonstrate the role of PHDs
in the effects of hypoxia on TSP-1, we knocked down the expression
of all three known PHDs (PHD1, PHD2 and PHD3) with specific
siRNAs. Silencing of the three PHDs did not affect the amount of
TSP-1mRNA transcripts (Fig. 4b left) but it did diminish the amount
of TSP-1 protein (Fig. 4b right). Furthermore, lack of changes on
HIF1a or HIF2a levels under these conditions support our conclu-
sion that TSP-1 is regulated during hypoxia independently ofHIF. By
contrast, overexpression of PHDs in RCC4 VHL positive cells (see
Supplementary Fig. S4 online), which express lower levels of PHDs
than RCC4, recovered the levels of TSP-1 protein during hypoxia
(Fig. 4c). Together, these results indicated that the hypoxia-mediated
decrease in PHD activity also contributes to the decrease in TSP-1
protein during hypoxia.
The levels of TSP-1 regulate ccRCC cell migration and invasion. It
has been shown that angiogenic factors stimulate ccRCC cell
migration, although the role of endogenous angiogenic inhibitors,
like TSP-1, in autocrine regulation of ccRCC cells remains unex-
plored. Taking this into account, we asked whether the decreased
TSP-1 protein levels during hypoxia play a functional role in ccRCC
cell migration and invasion. Accordingly, we first performed RCC4
cell migration assays under normoxic or hypoxic conditions,
observing an increase in cell migration under hypoxic conditions
(Fig. 5a). To determine whether the loss of TSP-1 during hypoxia
influenced cell migration, purified TSP-1 was added to the RCC4
cells and migration was assessed under normoxic or hypoxic condi-
tions. When the cells were exposed to exogenously added TSP-1
(66 nM), FBS or LPA-stimulated migration was significantly inhi-
bited in both normoxia and hypoxia (Fig. 5b). Furthermore, the
RCC4 cells were transfected with a specific siRNA directed against
TSP-1 (Fig. 5c left) and migration assays were performed by sti-
mulating with FBS. TSP-1 silencing produced a significant increase
in RCC4 cell migration compared to the cells transfected with
scrambled RNA (Fig. 5c right). This increased migration was also
inhibited by adding exogenous TSP-1 into the upper chamber
(Fig. 5d). Moreover, similar results were observed when migration
was analyzed in wound healing assays (see Supplementary Fig. S5
online). In addition cells transfected with TSP-1 siRNA were also
analyzed for their ability to invade through a type I collagen matrix,
demonstrating a significant increase in cell invasion associated with
TSP-1 silencing (Fig. 5e). Taken together, these results indicate that
TSP-1 produced by ccRCC cells can inhibit migration in response to
various chemoattractants. Subsequently, hypoxia-mediated decrease
in TSP-1 protein levels stimulates ccRCC cell migration and invasion.
Discussion
RCC is the most commonmalignant tumour of the adult kidney and
despite recent advances in diagnostic imaging, patients are typically
diagnosed at an advanced stage. Therefore, studies of the molecular
biology of these tumours can only benefit their management.
Inactivation of tumour suppressor genes directly influences the
angiogenic phenotype of these tumours, altering the relative amounts
of inducers and inhibitors they secrete. In addition, the tumour
microenvironment exerts selective pressure that favours the regu-
lation of specific genes involved in tumour progression, for example
when conditions of hypoxia arise. While such pressure may affect
genes involved in angiogenesis, cell proliferation, cell-cell and cell-
matrix interaction proteins, it may also involve downregulation of
genes that inhibit tumour growth and angiogenesis2. Our studies
in ccRCC cell lines indicated that a hypoxic microenvironment
diminishes the levels of TSP-1, an inhibitor of angiogenesis, which
proved to influence ccRCC behaviour, enhancing the migratory and
invasive potential of these cells in in vitro assays.
The importance of TSP-1 in renal cancer has been demonstrated
previously38–40. In these reports it is shown that TSP-1 is important in
maintaining normal kidney angiostasis, and its expression inversely
correlates with microvascular density, proliferation and RCC pro-
gression. However, the effect of the hypoxic microenvironment on
these tumours has not previously been assessed, nor whether it may
regulate TSP-1 levels. The increase in angiogenesis in response to
hypoxia is part of the adaptive response that aims to achieve
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Figure 2 | TSP-1 regulation in RCC cell lines is independent ofHIF. TSP-
1 and HIF2a protein levels in 786-O cells transfected with a scrambled
siRNA (scr), or siRNAs specific for HIF2a (siHIF2a) were analyzed after
24 h under normoxic or hypoxic conditions (left panel). TSP-1, HIF2a
andHIF-1a protein levels in RCC4 cells transfected with scrambled (scr) or
siRNA to HIF-1a (siHIF1a) or HIF-2a (siHIF2a) were analyzed after 24 h
in normoxic or hypoxic conditions (right), with a-tubulin as a loading
control. The results are representative of at least three experiments
performed.
www.nature.com/scientificreports
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enhanced oxygen and nutrient delivery to growing tissues. Hence, a
hypoxia-mediated decrease in TSP-1 protein in ccRCC cell lines
could be part of the hypoxic metastatic programme. The decrease
in TSP-1 expression during hypoxia has been shown previously in
other immortalized and tumour cells31,36. By contrast, hypoxia aug-
ments the TSP-1 in endothelial cells, coronary artery smooth muscle
cells and in human dermal fibroblasts30,32,34,35. These results indicate
that TSP-1 affects tumourigenesis by inducing different biological
effects in distinct cell types. In hypoxic endothelial cells, the induc-
tion of TSP-1 might be a negative feedback mechanism to counter-
balance the effect of pro-angiogenic factors such as VEGF.
Conversely, tumour cells decrease the levels of anti-angiogenic fac-
tors in hypoxic conditions in order to favour their own survival and
growth.
The mechanisms that regulate TSP-1 in hypoxia may differ in
distinct cell types as hypoxia may induce TSP-1 by enhancing
mRNA stability34 or through transcriptional regulation mediated
by HIF-1a30,32. However, hypoxia decreases TSP-1 through post-
transcriptional mechanisms31,36. While there are only a few known
examples of genes repressed byHIF44,45, the expression ofmany genes
is repressed during hypoxia independently of HIF. In this respect,
recent genome-wide bioinformatics or experimental studies7,8 have
demonstrated that HIF-binding is mainly associated with the upre-
gulation of gene expression. Transcriptional repression does not
seem to be directly mediated by HIF, which is consistent with our
observations that the loss of TSP-1 during hypoxia is HIF-independ-
ent. Therefore, in our tumour cells themechanisms thatmay account
for the decrease in TSP-1 associated with hypoxia may include post-
transcriptional, translational or post-translational mechanisms.
It was previously shown that 39 and 59-untranslated region (UTR)
of the TSP-1 mRNA transcript are involved in post-transcriptional
regulation, either affecting mRNA stability or mRNA translation46,47.
However we found no significant differences in the activity of a
reporter fused to the TSP-1UTR in compared normoxic and hypoxic
conditions (unpublished results). Regulation by miRNAs was also
considered since TSP-1 is a target for repression by the miR-17-92
microRNA cluster in human adenocarcinoma48. Indeed, miR-21
may be upregulated in ccRCC tissue and this miRNA can also be
induced by hypoxia49,50. Surprisingly, in hypoxic conditions we did
not detect induction of this miRNA in our cell lines (unpublished
results) and therefore, the decrease of TSP-1 levels during hypoxia is
not likely to be mediated by the microRNAs reported to regulate
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Figure 3 | Role ofAkt signalling in the regulation of TSP-1 protein during hypoxia. a) TSP-1 protein levels were analyzed in total lysates fromRCC4 cells
cultured for 24 h under normoxic or hypoxic conditions in the presence of vehicle alone (2) or with 6-12 mM LY294002 (LY). Total Akt and
phosphorylated Akt (pAkt) were analyzed in the same samples. TSP1 protein was quantified by densitometry and the change in TSP-1 in LY-treated cells
was calculated. b) TSP-1 mRNA expression in RCC4 cells cultured under normoxic or hypoxic conditions in the presence or absence of LY for 24 h was
quantified by quantitative RT-PCR. The mRNA levels were normalized to beta-actin and gene expression was represented as the fold induction during
hypoxia against the levels during normoxia. c) TSP-1, total Akt and phosphorylated Akt levels were analyzed in total lysates from RCC4 cells transfected
with the indicated amounts of a plasmid encoding the empty vector (pCMV6) or a constitutive active form of Akt (gagAkt). TSP-1 protein levels were
quantified as in a) and normalized to a-tubulin. d) TSP-1 mRNA expression in RCC4 cells transfected with 1 mg of pCMV6 or gagAkt. Gene expression
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TSP-1 production. TSP-1 mRNA may also be regulated by uncoup-
ling from polysomes, such as in response to high glucose47. However,
we found no significant differences when the TSP-1 mRNA in the
polysomal and non-polysomal fractions were analyzed (unpublished
results).
It was previously shown that Akt signalling can both positively and
negatively affect TSP-1 levels in endothelial cells from different
sources40,51,52, yet our results proved that Akt signalling diminished
the amount of TSP-1 protein in RCC cells. In a recent report by Kaur
S. et al.53 the authors found that TSP-1, through its binding to CD47,
potently inhibits VEGFR2 signalling and the downstream activation
of Akt. Based on these results, it is possible that TSP-1 might also
inhibit Akt phosphorylation in RCC cells and therefore, the
decreased TSP1 expression under hypoxia could provoke, rather
than only represent a consequence of the increased levels of phos-
phorylated Akt. However, the knockdown of TSP-1 in our RCC cells
under normoxic conditions did not affect Akt phosphorylation .
Another possibility is that PHDs may be responsible for the changes
in Akt phosphorylation and the decrease in TSP-1. In this respect, it
was previously shown that inhibiting PHDswith deferroxamine aug-
ments Akt phosphorylation42, and on the other hand the activity of
PHDs is also regulated by hypoxia (reviewed in2). The silencing of
PHDs with specific siRNA, or their inhibition, produces a consistent
decrease in TSP1 protein in ccRCC. By contrast, over-expression of
PHDs in hypoxia partially recovered the decrease in TSP-1.
However, and despite the fact that in other cell lines we observed
diminished Akt phosphorylation when PHDs were over-expressed
during hypoxia (unpublished results), PHDs did not appear to affect
Akt phosphorylation levels in ccRCC cell lines. However, our results
indicated that PHDs can at least partially counteract the negative
effect of phosphorylated Akt on TSP-1 levels in hypoxia. While
PHDs have targets other than HIF, the regulatory influence of the
hydroxylation of these targets is not completely clear54. These results
are very interesting given that TSP1 could be another target of PHDs,
and on the other hand, PHDs could regulate tumour behaviour
independently of HIF by acting as a tumour suppressor. Further
studies will be necessary to understand the mechanisms by which
PHDs regulate TSP-1, and how the PHD pathway interacts with the
Akt signalling to regulate the levels of TSP-1 during hypoxia.
The effects of anti-angiogenic inhibitors may be bypassed by
tumour cells, either by increasing the expression of pro-angiogenic
factors or by decreasing the expression of those factors that inhibit it.
Here, we show that hypoxia can stimulate multiple signals which
contribute to the decrease in TSP-1 levels in ccRCC, influencing
ccRCC behaviour (Fig. 6). Several reports have demonstrated that
TSP-1 induces tumour cell migration, however in our model, we
found that TSP-1 inhibits ccRCC cell migration in response to dif-
ferent stimuli. These results reinforce the pleiotropic nature of TSP-1
and depending on the environmental conditions, the presence of its
different receptors may have different, even opposite, effects on cell
behaviour and biological process. TSP-1 can promote or inhibit
angiogenesis, and promote or inhibit tumour growth. Our results
demonstrate that in addition to its previously reported anti-angio-
genic activity on renal carcinomas, TSP1 suppression by hypoxia can
elicit autocrine stimulation of ccRCC migration that might be
important for the tumour outcome. Further studies aimed at under-
standing the exact mechanisms regulating TSP-1 in ccRCC will be
beneficial to the design of new therapies against these tumours.
Methods
Cell culture. The 786-O and RCC4 cell lines55 were cultured in RPMI 1640 with
GLUTAMAX-I (Invitrogen, San Diego, CA) supplemented with 10% fetal bovine
serum (FBS), 100 units/ml penicillin and 100 mg/ml streptomycin, and they were
maintained at 37uC in the presence of 5% CO2 and 21% O2 (normoxia). For hypoxic
or anoxic experiments, cells were incubated at 37uC in an Invivo2 400 hypoxia
workstation (Ruskinn Technology, West Yorkshire) in the presence of 5% CO2 and
1% or 0.1% oxygen, respectively, for the times indicated. When hypoxia and
reoxygenation cycles were performed, the cells were seeded at 10–20% confluence and
then subjected to hypoxia (1%O2) or normoxia for up to 24 h. Subsequently, the cells
were maintained in normoxia for 6–48 h.
Antibodies and reagents.Themonoclonal Ab-11 anti-TSP-1 antibody, (clones D4.6,
AG.1, MBC 200.1) was obtained from Neomarkers Lab Vision (Freemont, CA) and
the polyclonal anti-HIF2a antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, Heidelberg, GE). The monoclonal anti-tubulin antibody was purchased
from Sigma (Madrid, Spain) and the monoclonal anti-HIF-1a antibody was from BD
Transduction Laboratories (San Jose, CA). The PHD1, PHD2 and PHD3 polyclonal
antibodies were from Bethyl laboratories (Montgomery, TX) while the polyclonal
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anti-pAkt and anti-Akt were from Cell Signalling (Danvers, MA). The antibodies
were used in western blots at the concentration suggested by the manufacturer.
Secondary polyclonal (GE Healthcare, Pittsburgh, PA) or monoclonal (Dako,
Carpinteria, CA) HRP-conjugated antibodies were used and detected by Immun-
StarTM WesternCTM kit (BioRad, Hertfordshire, UK). LY294002 was fromMerck and
was used at the concentrations indicated. The Oleoyl-L-alpha lysophosphatidic acid
(LPA) was from Sigma and the Dimethyloxaloylglycine (DMOG) was from Enzo Life
Sciences (Farmingale, NY).
Conditioned media preparation. Soluble secreted TSP-1 was analyzed in
concentrated cell conditioned medium. Cells were cultured in the absence of FBS for
24 h under normoxia or hypoxia, and afterwards, the conditionedmedium (CM) was
collected, centrifuged and treated with a protease inhibitor cocktail (Roche). The CM
was then concentrated 100x times using Amicon Ultra (Millipore, Billerica, MA,
USA) devices with 50 kDa cut-off.
siRNA-mediated gene silencing. siRNA experiments were carried out with specific
pools of siRNAs directed against human TSP-1, HIF1a, HIF2a, PHD1, PHD2 or
PHD3 (Santa Cruz) or with a non-targeted pool of control siRNAs (scr). Cells were
transfected with Lipofectamine 2000 (Invitrogen), according to the manufacturer´s
instruction.
Real time PCR analysis. To determine the changes in gene expression induced by
hypoxia or the effects of gene silencing, quantitative RNA analysis was performed by
Real Time PCR with StepOne Plus (Applied Biosystems, Carlsbad, CA). Cells were
grown to 95% confluence in 60 mm culture dishes, and the total RNA was isolated
from cells using the Ultraspec RNA Isolation System (Biotecx Laboratories, Houston,
TX). RNA (1 mg/sample) was reverse-transcribed to cDNA with Improm II RT
(Promega, Madison,WI) in a final volume of 20 ml. For Q-RT-PCR 1 ml of cDNAwas
amplified with the specific primers pairs using the following temperature cycles:
10 min initial denaturation at 95uC; 15 s denaturation at 95uC, 1 min annealing at
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Figure 5 | Effect of TSP-1 levels on RCC cell migration and invasion. a) RCC4 cells were cultured under normoxic or hypoxic conditions for 48 h, after
which migration was assessed in transwell assays. Cells (20 3 103 cells/well) were seeded on top of the transwells and allowed to migrate for 16 h under
normoxic or hypoxic conditions. As a chemoattractant LPA (10 mM) was added to the lower chamber. b) RCC4 cells were cultured under normoxic or
hypoxic conditions for 48 h. Afterwards cell migration stimulatedwith 5%FBS or 10 mMLPA in the lower chamber was assessed for 16 h under normoxia
(Nx) or hypoxia (Hp) in the absence (2) or presence (1) of 66 nM TSP-1. c) Cells were transfected with TSP-1 or scrambled (scr) siRNA and the
efficiency of the interference on TSP-1 protein levels was analyzed inWestern blotts (left panel). Cell migration stimulated by 5% FBS was analyzed after
transfection. The proportion of migrating cells (% over scr) and a representative photomicrograph is shown. d) Cells transfected as in c) were allowed to
migrate in the absence or presence of 66 nM TSP-1 using LPA (10 mM) as a chemoattractant. The average number of cells that migrated in three random
fields was calculated and cell migration was represented as the percentage of cells that migrated (6 SEM). n$3 in all panels, *p#0.05, **p#0.01,
Students-T test. e) Cells transfected with TSP-1 siRNA or scramble (scr) were allowed to invade through type I collagen coated inserts. The values in the
graph represent the cells that invaded (average number of cells 6 SEM). *p#0.05, Students-T test.
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60uC and extension over 40 cycles. Melting curves were obtained at 95uC for 15 s,
60uC for 1 min and 95uC for 15 s, labelling samples with power SYBR green (Applied
Biosystems). The primer pairs used were: TSP-1 (F: ACT GGG TTG TAC GCC ATC
AGG; R: CTA CAG CGA GTC CAG GAT CAC), HPRT (F: ATT GTA ATG ACC
AGT CAA CAG GG; R: GCA TTG TTT TGC CAG TGT CAA), VEGF
(F: TGCCAAGTGGT CCCAG; R: GTGAGGTCT TGATCCG), PHD1
(F: GCGCTGCATCACCTGTATCTAT; R: CCGC CATGCACCT TAACG, PHD2
(F: CCCTCATGAAGTACAACCAGCAT; R: CATCTGCATCAA
AATACCAAACAGT) PHD3 (F:TGCATCACCTGCATCTACT ATCTG;
R:TACATGGTGGGATCCTGCG) and GLUT-1 (F: TCAACCGCAACGA
GGAGAA; R: CTGTCCCGCGCAGCTT).
DNA cell transfection. RCC4 cells were transfected with a plasmid encoding a
constitutive active form of Akt (gagAkt) or with the empty vector (pCMV6: plasmids
kindly provided by Dr Ana Clara Carrera, CNB, Madrid, Spain). The cells were also
transfected with plasmids encoding PHD1, PHD2 and PHD3 (PCDNA3-PHD1:flag,
PHD2:flag and PHD3:flag) or the empty PCDNA3 vector as a control. Briefly, cells
were seeded and grown to 50–70% confluence, and then transfected using the jetPEI
reagent (Genycell Biotech, Spain). For the gagAkt or PCMV6 plasmids, 1 or 2 mg of
DNA/p60 was diluted in 48 ml of 150 mMNaCl. Separately, 4 ml of jetPEI reagent was
diluted in 46 ml of 150 mMNaCl andmixed with theDNA solution. Thismixture was
vortexed, incubated for 20 min at room temperature, and then added to the cells. The
cell media was completed to 2 ml final volume containing 10% of FBS and 1% of
penicillin and streptomycin, and after transfection the cells were cultured for 36 h
before they were used in the experiments. When transfected with PCDNA3-PHD1,
PHD2 and PHD3:flag, or the empty vector PCDNA3, 10 mg of each plasmid or vector
was used, and 48 h post-transfection, the cells were subjected to serum deprivation.
The cells were then processed 24 h post-deprivation, and protein or mRNA levels
were analyzed in western blots (total lysate) or by Q-RT-PCR.
Cellmigration and invasion assays.Migration and invasion assays were evaluated in
Transwell filters (6.5-mm diameter, 8 mm pore size: from Costar Corning, NY). The
ccRCC cells serum starved for 24 hwere seeded in the upper transwell (203 103 cells/
well in 160 ml RPMIwithout FBS) in the presence or absence of 60 nMTSP-1 (Athens
Research & Technology, GA), and they were allowed to migrate for 16 h at 37uC. As
chemoattractants, RPMI with 5% FBS or 10 mM LPA were added in the lower
chamber, using basal media as a negative control. The cells in the upper surface of the
membrane that did not migrate were gently removed with Q-tips, while the cells on
the lower surface were fixed, stained with Diff-Quick (International Reagent, Kobe,
Japan) and counted under the microscope (20X). An average of three random fields
per condition were analysed. For invasion assays, the cells were loaded on top of
Transwell filters previously coated with Collagen type I (20 mg/ml) and the
experiment was carried out over 16–18 h.
Statistical analysis. Each experiment was repeated at least three times and the results
were expressed as the mean 6 SEM. Statistical significance was determined with the
Students-T test and a p # 0.05 was considered significant.
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